Senti Bio is using synthetic biology to build intelligence into cell and gene therapies, altering the way they act depending on the changing biological circumstances they may encounter in the body. Doing so may lead to safer and more effective therapies and address such things as the tumor microenvironment and mechanisms cancer have to grow, spread, and become resistant to treatments. Ahead of his appearance at the SynBioBeta conference that runs October 1-3 in San Francisco, we spoke to Tim Lu, co-founder and CEO of Senti Bio, about the company’s efforts to engineer a new class of intelligent medicines, its ability to design therapies that hit multiple targets, and its strategy to leverage its technology to reach beyond oncology through partnerships.